Acorda To Present New Research On Novel Multiple Sclerosis And Epilepsy Therapies At American Academy Of Neurology 65th Annual Meeting

Acorda Therapeutics, Inc. (Nasdaq:  ACOR) will present new research data at the 65 th American Academy of Neurology Annual Meeting on AMPYRA ® (dalfampridine) Extended Release Tablets, 10 mg, an FDA-approved therapy indicated to improve walking in people with multiple sclerosis, and Diazepam Nasal Spray, an investigational therapy for the treatment of cluster seizures, also known as acute repetitive seizures, in people with epilepsy.

“Acorda is focused on improving the lives of people with neurological disorders. We currently are developing seven therapies for a range of conditions, including multiple sclerosis, epilepsy and spinal cord injury,” said Ron Cohen, M.D., Acorda Therapeutics’ President and CEO. “Our presentations at AAN include new studies on AMPYRA and the first clinical data presented on Diazepam Nasal Spray. These studies have increased our understanding of the potential roles these therapies could have in addressing the urgent needs of patients with these conditions.”

Data being presented on Acorda-developed therapies at the AAN annual meeting include:
  • Changes in Gait, Walking, and Balance Parameters After Withdrawal and Re-initiation of Dalfampridine Extended Release Tablets in Patients with Multiple Sclerosis: Results from the STEADY Study – P04.103 being presented Wednesday, March 20 th, 7:30am – 12:00pm
  • Safety and Efficacy of 5mg and 10mg Dalfampridine Extended Release Tablets in Patients with Multiple Sclerosis: First Results from a Double-Blind, Placebo-Controlled Trial – P04.096 being presented Wednesday, March 20 th, 7:30am – 12:00pm
  • Effects of 5mg and 10mg Dalfampridine Extended Release Tablets on 6-Minute Walk Distance in People with Multiple Sclerosis: A Subgroup Analysis of a Double-Blind, Placebo-Controlled Trial – S01.007 being presented Tuesday, March 19 th at 2:30pm
  • Assessment of Pharmacokinetic Linearity and Relative Bioavailability of a Nasal Diazepam Formulation Compared with Diazepam Rectal Gel In Healthy Adult Subjects – P02.214 being presented Tuesday, March 19 th, 7:30am – 12:00pm

More detailed information on scientific sessions and data presentations at the AAN annual meeting can be found on the conference website ( http://www.aan.com/go/am13).

Important Safety Information

Do not take AMPYRA if you have ever had a seizure or have certain types of kidney problems.

If you liked this article you might like

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

Acorda Stiff-Arms Investor's Demand for Sale

Biotech Movers: Adamis Shares Jump After FDA Approves Epinephrine Pre-filled Syringe